These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25297990)

  • 1. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer.
    Aoyama T; Katayama Y; Murakawa M; Asari M; Kanazawa A; Higuchi A; Shiozawa M; Kobayashi S; Ueno M; Morimoto M; Ohkawa S; Akaike M; Yamamoto N; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1235-40. PubMed ID: 25297990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer.
    Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
    Gastric Cancer; 2013 Apr; 16(2):133-9. PubMed ID: 22527186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
    Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Yamada T; Tsuchida K; Hasegawa S; Cho H; Yukawa N; Oshima T; Rino Y; Masuda M; Tsuburaya A
    Ann Surg Oncol; 2013 Jun; 20(6):2000-6. PubMed ID: 23242818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer.
    Aoyama T; Kawabe T; Fujikawa H; Hayashi T; Yamada T; Tsuchida K; Yukawa N; Oshima T; Rino Y; Masuda M; Ogata T; Cho H; Yoshikawa T
    Ann Surg Oncol; 2015 Aug; 22(8):2560-6. PubMed ID: 25515199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients.
    Aoyama T; Katayama Y; Murakawa M; Atsumi Y; Yamaoku K; Kanazawa A; Higuchi A; Shiozawa M; Kobayashi S; Ueno M; Morimoto M; Yamamoto N; Oshima T; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1115-20. PubMed ID: 25821166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.
    Shinkawa H; Uenishi T; Takemura S; Sakata C; Urata Y; Nozawa A; Hamano G; Kinoshita M; Kubo S
    Hepatogastroenterology; 2015; 62(137):169-74. PubMed ID: 25911890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
    Tsuchiya T; Nagayasu T; Yamasaki N; Matsumoto K; Miyazaki T; Tagawa T; Nakamura A; Minami H; Taniguchi H; Akamine S; Hisano H; Taniguchi Y
    Clin Lung Cancer; 2012 Nov; 13(6):464-9. PubMed ID: 22424872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Continuous administration and safety of S-1 in adjuvant chemotherapy for gastric cancer].
    Kimura M; Morihata K; Ito D; Iwai M; Okada K; Usami E; Nakao T; Yoshimura T; Yasuda T
    Gan To Kagaku Ryoho; 2010 May; 37(5):829-34. PubMed ID: 20495311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
    N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil and oteracil potassium) for colorectal cancer.
    Kawahara H; Watanabe K; Ushigome T; Noaki R; Kobayashi S; Yanaga K
    Hepatogastroenterology; 2012; 59(113):134-7. PubMed ID: 22251528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.
    Aoyama T; Murakawa M; Katayama Y; Shiozawa M; Ueno M; Morimoto M; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Hepatogastroenterology; 2015; 62(138):472-7. PubMed ID: 25916085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
    Wada T; Kunisaki C; Hasegawa S; Takagawa R; Momiyama M; Kosaka T; Makino H; Ono HA; Oshima T; Akiyama H; Endo I
    Anticancer Res; 2013 Apr; 33(4):1747-51. PubMed ID: 23564827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Factors for Poor Compliance with Adjuvant S-1 Chemotherapy for Gastric Cancer: A Multicenter Retrospective Study.
    Yamashita K; Kurokawa Y; Yamamoto K; Hirota M; Kawabata R; Mikami J; Masuzawa T; Takiguchi S; Mori M; Doki Y
    Ann Surg Oncol; 2017 Sep; 24(9):2639-2645. PubMed ID: 28608116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
    Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
    Ann Surg Oncol; 2012 May; 19(5):1568-74. PubMed ID: 22143578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Examination of s-1 therapy for adjuvant chemotherapy in patients with advanced gastric cancer].
    Matsui K; Nashimoto A; Yabusaki H; Nakagawa S; Nomura T; Takii Y; Tsuchiya Y; Tanaka O
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):953-7. PubMed ID: 19542714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.
    Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
    Gastric Cancer; 2011 Aug; 14(3):274-8. PubMed ID: 21461654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.
    Hayashi K; Imaizumi T; Uchida K; Kuramochi H; Takasaki K
    Oncol Rep; 2002; 9(6):1355-61. PubMed ID: 12375048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Alternate-day oral therapy with S-1 for adjuvant chemotherapy of gastric cancer].
    Takebayashi K; Kawai Y; Tagi T; Matsumura M; Shimizu K; Yamamoto H; Mekata E; Tani T; Sato M
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):385-7. PubMed ID: 22421764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
    Ito S; Ohashi Y; Sasako M
    BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer.
    Jeong JH; Ryu MH; Ryoo BY; Lee SS; Park I; Lee SH; Kim KC; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):523-9. PubMed ID: 22864947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.